Scientific Advisory Committee

The Scientific Advisory Committee (SAC)

The Scientific Advisory Committee is an advisory committee to the MAC. The SAC assists investigators in the development of new study proposals, oversees ongoing studies and advises the MAC on scientific matters that may arise.

If you would like to be involved in the ALTG Advisory Committee or a sub-group committee, please contact us so we can discuss this further.

Members and roles

Nick Pavlakis – President of the Scientific Advisory Committee (SAC)

A/Prof Nick Pavlakis underwent undergraduate medical training at the University of NSW and graduated in 1991. He underwent general medical training and subsequent advanced training in Medical Oncology at Royal North Shore Hospital, completing FRACP in 1997.

He then spent 3 years completing a PhD in new cancer drug development involving an Australian developed anti-angiogenic compound PI-88 (Progen Industries and ANU); and a Masters of Clinical Epidemiology through the University of Sydney. He has worked in private oncology practice since 1998 and has been a practice member of the Northern Cancer Institute since 2001. He is current Chair of the Lung Cancer Group of the Clinical Oncologic Society for Australa (COSA), and is Regent for Australasia for the International Association for the Study of Lung Cancer (IASLC).

Paul Mitchell – Past President

Dr Paul Mitchell holds the positions of medical oncologist at the Olivia Newton-John Cancer and Wellness Centre at Austin Health in Melbourne, Director of the North-Eastern Melbourne Integrated Cancer Service (Cancer Network), and is an associate professor at the University of Melbourne. Dr Mitchell was President of the Australasian Lung Cancer Trials Group (ALTG) 2012–2016 and has been involved in clinical and laboratory research for over 20 years. He is Chairman of the Thoracic Alliance for Cancer Trials (TACT) which brings together national and trans-national lung cancer trials groups. He also sits on the State Government Cancer Quality and Outcomes Committee and the Program Assessing Committee of the Health Research Council of New Zealand.

Ben Solomon – Chair

Professor Ben Solomon is a medical oncologist in the Lung Service and the Head & Neck service. He is the Group Leader of the Molecular Therapeutics and Biomarkers Laboratory in the Research Division. He completed a PhD investigating the mechanisms by which EGFR inhibition enhance the effects of radiation, and subsequent postdoctoral studies at the University of Colorado investigating novel predictive markers for therapy with EGFR inhibitors. Professor Solomon practices as a medical oncologist with a research focus on clinical and translational research in lung cancer and head and neck cancer at Peter Mac. His clinical trial work focuses on the identification of novel therapies for lung cancer.

Tom John – Deputy Chair

Dr Tom John is a Consultant Medical Oncologist at the Olivia Newton John Wellness Centre. His research interests currently involve the development and validation of Molecular Predictive and Prognostic Markers in Non-Small Cell Lung Cancer and the performance of clinical trials evaluating targeted biologic agents and small molecule inhibitors in lung cancer. He recently published a study demonstrating that Cancer Testis (CT) antigens are not only poor prognostic markers, but also predict tumours likely to respond to chemotherapy.

Photo coming soon
Antony Mersiades – Clinical Research Fellow

Biography coming soon.

Martin Stockler – CTC Clinical Lead

Martin Stockler is Professor of Cancer Medicine and Clinical Epidemiology, Sydney Medical School, Oncology Co-Director at the NHMRC Clinical Trials Centre, University of Sydney, and a Medical Oncologist at the Concord Cancer Centre and Chris O’Brien Lifehouse RPA in Sydney. Martin’s research aims to improve survival, quality of life, care, and communication for those affected by cancer. His methodological interests include clinical trials, meta-analysis, patient-rated outcome measures, and prognostication.

Chris Brown – Data Centre Representative, Statistics

Biography coming soon.

Fraser Brims – Subgroup Co-Chairs, Early Diagnosis and Screening

A/Prof Fraser Brims is a Consultant Respiratory Physician at Sir Charles Gairdner Hospital and Director of Early Years Communication and Clinical Skills at Curtin University Medical School, based in Perth, Western Australia (WA). Prof Brims has a clinical and research interests in early lung cancer detection and he leads the WA Asbestos Review Program, a prospective longitudinal cohort of ~1,750 individuals with annual low dose CT scans for the detection of early lung cancer.

Annette McWilliams – Subgroup Co-Chairs, Early Diagnosis and Screening

Dr Annette McWilliams is a Respiratory Physician who trained in Western Australia and subsequently moved to Vancouver, Canada where she spent 12 years working at the British Columbia Cancer Agency and Vancouver General Hospital. She returned to work in Perth in early 2013 and is Clinical Lead for the Thoracic Tumour Collaborative of WA. Dr. McWilliams is continuing her interest in early lung cancer detection and is a member of the IASLC Prevention, Screening and Early Detection Committee. She was the inaugural Head of Respiratory Medicine at the new Fiona Stanley Hospital that acts as the comprehensive cancer centre for the southwest region of Western Australia.

Steven Kao – Subgroup Co-Chairs, Mesothelioma

Dr Steven Kao is a medical oncologist at the Chris O’Brien Lifehouse, Camperdown. He completed his PhD at the ADRI and focused his research on predictive and prognostic factors in malignant mesothelioma. Steven has a wide clinical, translational and psycho-social research interest in thoracic cancers including malignant mesothelioma and asbestos-related lung cancers. He was awarded the Premier’s Award for Outstanding Cancer Research Scholar from the Cancer Institute NSW in 2012.

Anna Nowak – Subgroup Co-Chairs, Mesothelioma

Professor Anna Nowak is an academic medical oncologist who treats and researches two invariably fatal cancer types: mesothelioma and malignant brain tumours. She has a PhD in tumour immunology and did a post-doctoral fellowship in clinical trials and quality of life research, giving her a unique perspective that truly bridges bench to bedside. Whilst speaking the language of scientists and having an active laboratory program, she is also a clinician who brings new treatments to patients through novel clinical trials. She is passionate about patient-doctor communication, mentoring, and women in oncology and science.

Ken O’Byrne – Subgroup Co-Chairs, NSCLC

Prof O’Byrne is a Consultant and Professor in Medical Oncology at the Princess Alexandra Hospital and the Queensland University of Technology. He has conducted translational ‘bench-to-bedside-and back-again’ research over the past 25 years with a focus on solid epithelial tumours, in particular in thoracic malignancies.  He is involved in the International Association for the Study of Lung Cancer (IASLC) and Thoracic Alliance for Cancer Trials (TACT) and a member of Australian Lung cancer Trials Group (ALTG), Medical Oncology Group of Australasia (MOGA) and Australian Genomics Health Alliance (AGHA).

Chee Lee – Subgroup Co-Chairs, SCLC

Dr. Chee Khoon Lee is a consultant medical oncologist, and a staff specialist at the St George Hospital and the Sutherland Hospital. He obtained his PhD from the University of Sydney in 2012 for his methodological work in the conduct of clinical trials involving biomarkers for personalising treatment in patients with advanced cancers.  He is the Director of the Clinical Research Unit (Medical Oncology) at St George Hospital. He actively enrolls patients into clinical studies that investigate novel therapeutic agents in lung, ovarian, and breast cancers.

Michael Millward – Subgroup Co-Chairs, SCLC

Professor Millward is the foundation Chair of Clinical Cancer Research, University of Western Australia and Head of Medical Oncology at Sir Charles Gairdner Hospital, Perth, Australia. He has a strong track record in delivering clinical trial outcomes, particularly with novel therapeutics and phase I/II studies. He is an international expert on thoracic malignancies and melanoma.

Haryana Dhillon – Subgroup Co-Chairs, Supportive and Palliative Care

Haryana is a Research Fellow in Cancer Survivorship at the Centre for Medical Psychology and Evidence-based Decision-making (CeMPED) University of Sydney. She is also a member of the Board of  the Clinical Oncological Society of Australia (COSA) and Council, and chair of the Survivorship Group of COSA. Haryana co-leads a Cancer Survivorship Research Group based in the University of Sydney.

Michael Franco – Subgroup Co-Chairs, Supportive and Palliative Care

Presently Respiratory Physician, Wyong Hospital. Previously Physician and lung cancer lead Peterborough Hospital, UK and member of lung cancer Team at Papworth Hospital, Cambridge UK. Respiratory physician and lung cancer lead Royal Hobart Hospital and clinical lead for Tasmanian Clinical Cancer Network.